Investigating how CD5 affects the immune response to tumors
The Role of CD5 in Tumor Immunity
This study is looking at a molecule called CD5 on special immune cells that help fight tumors, like melanoma, to see how they work in healthy people compared to those with cancer, with the goal of finding better ways to boost the immune system's response to tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10866358 on NIH RePORTER |
What this research studies
This research explores the role of a specific molecule called CD5 on dendritic cells, which are crucial for initiating anti-tumor immune responses. The study aims to understand how different subsets of these cells function in humans, particularly in the context of diseases like melanoma. By examining the presence and activity of CD5+ dendritic cells in healthy versus tumor-affected tissues, the researchers hope to uncover new ways to enhance T cell activation and improve immune responses against tumors. The methodology includes both human tissue analysis and pre-clinical mouse models to validate findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma or other cancers where dendritic cell function may be compromised.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not involve dendritic cell interactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy strategies that enhance the body's ability to fight tumors, potentially improving outcomes for cancer patients.
How similar studies have performed: Previous research has shown promise in enhancing immune responses through dendritic cell manipulation, suggesting that this approach could be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Klechevsky, Eynav Yafit — Washington University
- Study coordinator: Klechevsky, Eynav Yafit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.